Phase 3 Study of Lumateperone as Adjunct to Antidepressant Therapy for Major Depressive Disorder and Anxious Distress Meets Endpoints
New phase 3 study data on lumateprone (Caplyta) as adjunctive therapy for patients with major depressive disorder and…